Video

Continuous Glucose Monitoring for Type 1 Diabetes

Author(s):

William Polonsky, PhD, CDE, explains where more benefits lie in T2D patients using the monitoring devices.

Continuous Glucose Monitoring (CGM) devices are not just for Type 1 diabetes (T1D) patients.

In fact, William Polonsky, PhD, CDE, would say Type 2 diabetes (T2D) patients receive more benefit from CGM than T1 patients do.

Polonsky, president of the Behavioral Diabetes Institute and an associate clinical professor at the University of California, San Diego, discussed recent research he led at the American Diabetes Association 77th Scientific Sessions in San Diego.

From what he learned in the study of GCM devices for T2D patients, the monitoring method goes appeciated.

"There were very, very high levels of treatment satisfaction — in fact, higher than any study I'm aware of," Polonsky said.

The T2D patients report more benefits to their own diabetes monitoring with newfound advantages in learning how lifestyle actions and decisions affect blood sugar, Polonsky said. Such information generally goes by unknown by the T2D patient group, and Polonsky hoped the study catches the ear of doctors.

"I hope this is really striking to healtchare providers as they're maybe reticent about the use of CGM data for Type 2's," Polonsky said. "At least from the point of personal treatment satisfaction, there's a huge amount of enthusiasm."

Related Coverage

How to Reduce Driving Mishaps in Patients with T1 Diabetes

Late Dinners Boost Blood Sugar, But "Divided Dinners" Don't

Insulin Resistance Accelerates T1 Diabetes in Children

Related Videos
Rahul Aggarwal, MD | Credit: LinkedIn
Brendon Neuen, MBBS, PhD | Credit: X.com
HCPLive Five at ADA 2024 | Image Credit: HCPLive
Ralph DeFronzo, MD | Credit: UT San Antonio
Timothy Garvey, MD | Credit: University of Alabama at Birmingham
Atul Malhotra, MD | Credit: Kyle Dykes; UC San Diego Health
Alexandra Louise Møller, MS, PhD | Credit: LinkedIn
A panel of 5 experts on Cushing's syndrome
A panel of 5 experts on Cushing's syndrome
Optimizing Diabetes Therapies with New Classifications
© 2024 MJH Life Sciences

All rights reserved.